Mr. Fengmin Xi joined InxMed in March 2023 as DMPK Director. Fengmin has more than 10 years of R&D experience in DMPK, toxicology and medicinal chemistry, additionally, along with rich investment and financing skills in biotechnology. He previously employed in a biotech boutique investment bank, HollyHigh, and engaged in investment and financing for biotech and CXO company. Prior to that, he worked for WuXi AppTec (603259.SH/2359.HK) and Medicilon (688202.SH) in clinical bioanalysis, preclinical DMPK and toxicology.
He held the Ph.D. in medicinal chemistry at Peking Union Medical College and Tsinghua University.